Post-marketing Drug Safety in the Era of Genomic Medicine

Cox D -2003-. Finding genetic hot spots using genome-wide scans. BioIT World. Available electronically at http://www.bio-itworld.com/news/040403_report2266.html -accessed 12/01/2004-.

Goldstein DB, Ahmadi KR, Weale ME, Wood NW -2003-. Genome scans and candidate gene approaches in the study of common diseases and variable drug responses. Trends Genet 19:615–622.

Harty LC, Garcia-Closas M, Rothman N, Reid YA, Tucker MA, Hartge P -2000-. Collection of buccal cell DNA using treated cards. Cancer Epid Biomarkers Prev 9:501–506.

Hinds DA, Stokowski RP, Patil N, Konvicka K, Kershenobich D, Cox DR, et al. -2004-. Matching strategies for genetic association studies in structured populations. Am J Hum Genet 74:317–325.

Hosono S, Faruqi AF, Dean FB, Du Y, Sun Z, Wu X, et al. -2003-. Unbiased whole-genome amplification directly from clinical samples. Genome Res 13:954–964.

Lord PG, Papoian T -2004-. Genomics and drug toxicity -editorial-. Science 306:575.

Meier B -2004-. Earlier Merck study indicated risks of Vioxx. New York Times 11/18/2004.

Psaty BM, Furberg CD, Ray WA, Weiss NS -2004-. Potential for conflict of interest in the evaluation of suspected adverse drug reactions. Use of cerivastatin and risk of rhabdomyolysis. J Am Med Assoc 292:2647–2650.

Strom BL -2004-. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. J Am Med Assoc 292:2643–2646.

Walker AM -2001-. Pattern recognition in health insurance claims databases. Pharmacoepidemiol Drug Safety 10:393–397.

Zavras AI -2004-. Using an administrative medical claims database to identify the pharmacogenetics of rare outcomes: scientific, ethical and social issues. In: Pharmacogenomics. Proceedings of the 2004 Cold Spring Harbor Laboratory Conference in Pharmacogenomics, Nov. 18–21, 2004. New York: CSHL, p. 115.